Subtotal: $25.00
Gene Therapy and Gene Editing Symposium
A brief overview of the strategy guiding efforts in gene therapy and gene editing, as well as critical updates from the companies in this space. Moderated discussion included.
Reed Clark, PhD
Chief Science Officer, Ultragenyx Gene Therapy
Ultragenyx
Alison Mcvie-Wylie, PhD
Vice President, Disease Area Executive, DMD
Vertex Pharmaceutical
Deanna Tucker, PharmD
Senior Medical Science Liaison
Sarepta Therapeutics